This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carver, R. S. Articles by Russell, W. E. Search for Related Content PubMed PubMed Citation Articles by Carver, R. S. Articles by Russell, W. E.

Hepatic Expression of ErbB3 Is Repressed by Insulin in a Pathway Sensitive to PI-3 Kinase Inhibitors¹

Departments of Cell Biology (R.S.C., W.E.R.), Pediatrics (W.E.R., P.M.M.), and the Vanderbilt Cancer Center (W.E.R.), Vanderbilt University, Nashville, Tennessee 37232

Address all correspondence and requests for reprints to: Dr. William E. Russell, Division of Pediatric Endocrinology, T-0101 Medical Center North, Vanderbilt University, Nashville, Tennessee 37232-2579. E-mail: bill.russell{at}mcmail.vanderbilt.edu

ErbB3 is an epidermal growth factor receptor-related type I tyrosine kinase receptor capable, in conjunction with ErbB2 or epidermal growth factor receptor, of transmitting proliferative and differentiative signals in a variety of cell types. We previously showed that ErbB3 messenger RNA and protein increase in cultured hepatocytes during the first 12 h in culture, as does the binding of heregulin ß1, a ligand for ErbB3. Insulin inhibits the increase in heregulin ß1 binding, as well as the increase in ErbB3 messenger RNA and protein. Two models of insulin deficiency in vivo (diabetes and fasting) demonstrated elevated levels of hepatic ErbB3 protein, strengthening the relevance of our observations in vitro. Using chemical activators or antagonists, we sought to identify the signaling pathways that link insulin to ErbB3 expression. The PI-3 kinase inhibitors, wortmannin and LY294002, completely blocked the inhibition of ErbB3 protein expression by insulin, suggesting a role for PI-3 kinase in the regulation of this growth factor receptor. Rapamycin, an inhibitor of p70 S6 kinase, an enzyme downstream of PI-3 kinase, failed to block the effect of insulin on ErbB3 expression. These results suggest a complex regulatory paradigm for ErbB3 that includes PI-3 kinase and may be linked, via insulin, to the metabolic status of the animal.

This article has been cited by other articles:

				L. A. Scheving, R. Buchanan, M. A. Krause, X. Zhang, M. C. Stevenson, and W. E. Russell Dexamethasone modulates ErbB tyrosine kinase expression and signaling through multiple and redundant mechanisms in cultured rat hepatocytes Am J Physiol Gastrointest Liver Physiol, September 1, 2007; 293(3): G552 - G559. [Abstract] [Full Text] [PDF]

				L. A. Scheving, L. Zhang, M. C. Stevenson, E. S. Kwak, and W. E. Russell The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling. Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G16 - G25. [Abstract] [Full Text] [PDF]

				I. H. Koumakpayi, J.-S. Diallo, C. Le Page, L. Lessard, M. Gleave, L. R. Begin, A.-M. Mes-Masson, and F. Saad Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2730 - 2737. [Abstract] [Full Text] [PDF]

				B. N. Kholodenko, O. V. Demin, G. Moehren, and J. B. Hoek Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor J. Biol. Chem., October 15, 1999; 274(42): 30169 - 30181. [Abstract] [Full Text] [PDF]